Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSCW) Total Current Liabilities (2020 - 2025)

Historic Total Current Liabilities for Ensysce Biosciences (ENSCW) over the last 6 years, with Q3 2025 value amounting to $2.3 million.

  • Ensysce Biosciences' Total Current Liabilities fell 1774.12% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year decrease of 1774.12%. This contributed to the annual value of $2.2 million for FY2024, which is 3377.68% down from last year.
  • According to the latest figures from Q3 2025, Ensysce Biosciences' Total Current Liabilities is $2.3 million, which was down 1774.12% from $2.5 million recorded in Q2 2025.
  • Ensysce Biosciences' 5-year Total Current Liabilities high stood at $16.5 million for Q4 2021, and its period low was $1.3 million during Q2 2024.
  • For the 5-year period, Ensysce Biosciences' Total Current Liabilities averaged around $5.5 million, with its median value being $3.7 million (2023).
  • Its Total Current Liabilities has fluctuated over the past 5 years, first skyrocketed by 145528.35% in 2021, then crashed by 8295.09% in 2023.
  • Quarter analysis of 5 years shows Ensysce Biosciences' Total Current Liabilities stood at $16.5 million in 2021, then tumbled by 42.58% to $9.5 million in 2022, then plummeted by 64.78% to $3.3 million in 2023, then tumbled by 33.78% to $2.2 million in 2024, then rose by 4.42% to $2.3 million in 2025.
  • Its Total Current Liabilities stands at $2.3 million for Q3 2025, versus $2.5 million for Q2 2025 and $1.8 million for Q1 2025.